Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Transplantation ; 101(12): 2855-2861, 2017 12.
Article in English | MEDLINE | ID: mdl-28471870

ABSTRACT

BACKGROUND: Insults to the airway epithelium play a key role in constrictive bronchiolitis after lung transplantation, the typical hallmark of chronic rejection. Our hypothesis is that immunosuppressives might affect airway integrity. METHODS: A biculture of human bronchial epithelial cells and lung microvascular endothelial cells was exposed to immunosuppressives (serum through levels) for 24 hours or 4 days. Cytotoxicity, transepithelial electrical resistance (TEER), and permeability was measured after exposure to monotherapies and combination therapies. Apoptosis, oxidative stress, inflammation (IL-8), real-time polymerase chain reaction for epithelial-to-mesenchymal transition and tight junction proteins were assessed in exposed cells. RESULTS: Mycophenolate mofetil (MMF) and combination therapies including MMF, at serum trough levels and higher, are toxic for the human bronchial epithelial cells after 4-day exposure. Moreover, already after 24 hours, TEER of cells exposed to MMF decreases and permeability increases. MMF did not induce apoptosis, oxidative stress, loss of tight junctions or production of IL-8 after 24 hours, but possibly induces epithelial-to-mesenchymal transition in epithelial cells. MMF was detectable at both sides of the biculture and was also present in bronchoalveolar lavage of lung transplantation patients. Other immunosuppressives were not toxic, neither changed TEER or permeability. CONCLUSIONS: Our findings suggest that MMF is present in the airways of lung transplant patients and might affect the structural integrity of the airway, which needs further investigation and validation in the clinical setting.


Subject(s)
Bronchiolitis Obliterans/drug therapy , Immunosuppression Therapy , Lung/drug effects , Azathioprine/administration & dosage , Cyclosporine/administration & dosage , Dexamethasone/administration & dosage , Endothelial Cells/metabolism , Epithelial Cells/metabolism , Epithelial-Mesenchymal Transition , Humans , Immunosuppressive Agents/therapeutic use , Inflammation/metabolism , Interleukin-8/metabolism , Lung/blood supply , Lung Transplantation , Microcirculation , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/therapeutic use , Permeability , Tacrolimus/administration & dosage , Tight Junctions/metabolism
2.
Adv Exp Med Biol ; 947: 325-344, 2017.
Article in English | MEDLINE | ID: mdl-28168673

ABSTRACT

The amount of experimental studies on the toxicity of nanomaterials is growing fast. Interpretation and comparison of these studies is a complex issue due to the high amount of variables possibly determining the toxicity of nanomaterials.Qualitative databases providing a structured combination, integration and quality evaluation of the existing data could reveal insights that cannot be seen from different studies alone. A few database initiatives are under development but in practice very little data is publicly available and collaboration between physicists, toxicologists, computer scientists and modellers is needed to further develop databases, standards and analysis tools.In this case study the process of building a database on the in vitro toxicity of amorphous silica nanoparticles (NPs) is described in detail. Experimental data were systematically collected from peer reviewed papers, manually curated and stored in a standardised format. The result is a database in ISA-Tab-Nano including 68 peer reviewed papers on the toxicity of 148 amorphous silica NPs. Both the physicochemical characterization of the particles and their biological effect (described in 230 in vitro assays) were stored in the database. A scoring system was elaborated in order to evaluate the reliability of the stored data.


Subject(s)
Nanoparticles/adverse effects , Databases, Factual , Humans , Nanostructures/adverse effects , Reproducibility of Results , Silicon Dioxide/adverse effects
3.
Transpl Int ; 30(4): 388-397, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28078769

ABSTRACT

Survival after lung transplantation is hampered by chronic lung allograft dysfunction (CLAD). Persistently elevated BAL-neutrophilia is observed in some patients despite treatment with azithromycin, which may be induced by IL-1α. Our aim is to establish an in vitro model, assess mechanistic pathways and test different therapeutic strategies of IL-1α-induced release of IL-8 by human bronchial epithelial cells. Bronchial epithelial cells (16HBE) were stimulated with IL-1α with or without azithromycin or dexamethasone. IL-8 protein was analyzed in cell supernatant. Different MAP kinases (p38, JNK, ERK1/2 , Iκß) and targets known to be involved in tumor formation (PI3K, Akt) were investigated. Finally, different treatment options were tested for their potential inhibitory effect. IL-1α induced IL-8 in bronchial epithelial cells, which was dose-dependently inhibited by dexamethasone but not by azithromycin. IL-1α induced p38 and Akt phosphorylation, but activation of these MAPK was not inhibited by dexamethasone. JNK, ERK1/2 , Iκß and PI3K were not activated. None of the tested drugs reduced the IL-1α induced IL-8 production. We established an in vitro model wherein steroids inhibit the IL-1α-induced IL-8 production, while azithromycin was ineffective. Despite using this simple in vitro model, we could not identify a new treatment option for azithromycin-resistant airway neutrophilia.


Subject(s)
Bronchi/metabolism , Epithelial Cells/metabolism , Interleukin-1alpha/metabolism , Interleukin-8/metabolism , Acetates/pharmacology , Acetylcysteine/pharmacology , Aminopyridines , Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Azithromycin/chemistry , Benzamides , Bronchi/drug effects , Cell Line , Cyclopropanes , Dapsone/pharmacology , Dexamethasone/chemistry , Dose-Response Relationship, Drug , Fluoroquinolones/pharmacology , Humans , MAP Kinase Signaling System , Moxifloxacin , Neutrophils/metabolism , Phosphorylation , Pyridones/pharmacology , Quinolines/pharmacology , Sulfides , Theophylline/pharmacology , Treatment Outcome
4.
Sci Rep ; 6: 37145, 2016 11 22.
Article in English | MEDLINE | ID: mdl-27872490

ABSTRACT

Nanomaterials are being extensively produced and applied in society. Human and environmental exposures are, therefore, inevitable and so increased attention is being given to nanotoxicity. While silica nanoparticles (NP) are one of the top five nanomaterials found in consumer and biomedical products, their toxicity profile is poorly characterized. In this study, we investigated the toxicity of silica nanoparticles with diameters 20, 50 and 80 nm using an in vivo zebrafish platform that analyzes multiple endpoints related to developmental, cardio-, hepato-, and neurotoxicity. Results show that except for an acceleration in hatching time and alterations in the behavior of zebrafish embryos/larvae, silica NPs did not elicit any developmental defects, nor any cardio- and hepatotoxicity. The behavioral alterations were consistent for both embryonic photomotor and larval locomotor response and were dependent on the concentration and the size of silica NPs. As embryos and larvae exhibited a normal touch response and early hatching did not affect larval locomotor response, the behavior changes observed are most likely the consequence of modified neuroactivity. Overall, our results suggest that silica NPs do not cause any developmental, cardio- or hepatotoxicity, but they pose a potential risk for the neurobehavioral system.


Subject(s)
Embryo, Nonmammalian/drug effects , Nanoparticles/toxicity , Silicon Dioxide/toxicity , Animals , Behavior, Animal/drug effects , Chemical and Drug Induced Liver Injury , Endpoint Determination , Heart/drug effects , Nanoparticles/chemistry , Particle Size , Silicon Dioxide/chemistry , Zebrafish
5.
Nanoscale ; 8(19): 9919-43, 2016 May 21.
Article in English | MEDLINE | ID: mdl-27143028

ABSTRACT

Nanotechnology is of increasing significance. Curation of nanomaterial data into electronic databases offers opportunities to better understand and predict nanomaterials' behaviour. This supports innovation in, and regulation of, nanotechnology. It is commonly understood that curated data need to be sufficiently complete and of sufficient quality to serve their intended purpose. However, assessing data completeness and quality is non-trivial in general and is arguably especially difficult in the nanoscience area, given its highly multidisciplinary nature. The current article, part of the Nanomaterial Data Curation Initiative series, addresses how to assess the completeness and quality of (curated) nanomaterial data. In order to address this key challenge, a variety of related issues are discussed: the meaning and importance of data completeness and quality, existing approaches to their assessment and the key challenges associated with evaluating the completeness and quality of curated nanomaterial data. Considerations which are specific to the nanoscience area and lessons which can be learned from other relevant scientific disciplines are considered. Hence, the scope of this discussion ranges from physicochemical characterisation requirements for nanomaterials and interference of nanomaterials with nanotoxicology assays to broader issues such as minimum information checklists, toxicology data quality schemes and computational approaches that facilitate evaluation of the completeness and quality of (curated) data. This discussion is informed by a literature review and a survey of key nanomaterial data curation stakeholders. Finally, drawing upon this discussion, recommendations are presented concerning the central question: how should the completeness and quality of curated nanomaterial data be evaluated?

6.
Nanotoxicology ; 10(5): 567-74, 2016.
Article in English | MEDLINE | ID: mdl-26525175

ABSTRACT

Nano-silicon dioxide (SiO2) is used nowadays in several biomedical applications such as drug delivery and cancer therapy, and is produced on an industrial scale as additive to paints and coatings, cosmetics and food. Data regarding the long-term biokinetics of SiO2 engineered nanoparticles (ENPs) is lacking. In this study, the whole-body biodistribution of SiO2 core-shell ENPs containing a paramagnetic core of Fe3O4 was investigated after a single exposure via intravenous injection or intratracheal instillation in mice. The distribution and accumulation in different organs was evaluated for a period of 84 days using several techniques, including magnetic resonance imaging, inductively coupled plasma mass spectrometry, X-ray fluorescence and X-ray absorption near edge structure spectroscopy. We demonstrated that intravenously administered SiO2 ENPs mainly accumulate in the liver, and are retained in this tissue for over 84 days. After intratracheal instillation, an almost complete particle clearance from the lung was seen after 84 days with distribution to spleen and kidney. Furthermore, we have strong evidence that the ENPs retain their original core-shell structure during the whole observation period. This work gives an insight into the whole-body biodistribution of SiO2 ENPs and will provide guidance for further toxicity studies.


Subject(s)
Ferrosoferric Oxide/pharmacokinetics , Lung/metabolism , Nanoparticles , Silicon Dioxide/pharmacokinetics , Administration, Inhalation , Animals , Ferrosoferric Oxide/administration & dosage , Ferrosoferric Oxide/chemistry , Humans , Injections, Intravenous , Instillation, Drug , Male , Mice , Mice, Inbred BALB C , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Organ Specificity , Silicon Dioxide/administration & dosage , Silicon Dioxide/blood , Silicon Dioxide/chemistry , Spectrometry, X-Ray Emission , Surface Properties , Tissue Distribution , X-Ray Absorption Spectroscopy
SELECTION OF CITATIONS
SEARCH DETAIL
...